Relay Therapeutics, INC Form 4 insider transactions

Donald A Bergstrom, President, R&D of Relay Therapeutics, Inc., sold 8,530 shares of common stock on September 8, 2026 for $18.97 per share.

Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., sold 17,717 shares of common stock on September 8, 2026 for $18.94 per share.

Sanjiv Patel, President and CEO and a Director of Relay Therapeutics, Inc., sold 48,199 shares of common stock on September 8, 2026 for $18.94 per share.

Peter Rahmer, See remarks of Relay Therapeutics, Inc., sold 4,508 shares of common stock on August 26, 2026 for $20.03 per share.

SVF Pauling (Cayman) Ltd and 2 others reported changes in beneficial ownership of Relay Therapeutics, Inc. common stock on August 25, 2026.

Sanjiv Patel, President and CEO and a Director of Relay Therapeutics, Inc., sold 48,199 shares of common stock on August 17, 2026 for $20.33 per share.

Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., sold 17,717 shares of common stock on August 14, 2026 for $19.74 per share.

Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., sold 1,459 shares of common stock on July 28, 2026 for $18.61 per share.

Peter Rahmer, See remarks of Relay Therapeutics, Inc., sold 748 shares of common stock on July 28, 2026 for $18.61 per share.

Donald A Bergstrom, President, R&D of Relay Therapeutics, Inc., sold 2,237 shares of common stock on July 28, 2026 for $18.61 per share.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc., reported the sale of 8,660 shares of common stock for $18.71 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Sanjiv Patel, President and CEO of Relay Therapeutics, has reported transactions involving the acquisition of shares through an Employee Stock Purchase Plan and the sale of shares under a Rule 10b5-1 trading plan.

Relay Therapeutics CFO Thomas Catinazzo reported the sale of 17,717 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Relay Therapeutics CFO Thomas Catinazzo reported transactions involving the sale and acquisition of company stock under a pre-arranged Rule 10b5-1 trading plan.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc., reported the sale of 93,456 shares of common stock under a pre-arranged 10b5-1 trading plan.

Director Claire Mazumdar was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Director Habib J. Dable was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Director Linda A. Hill was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Director Alexis Borisy was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Relay Therapeutics director Douglas S. Ingram was granted 32,947 stock options as part of standard equity compensation.

Director Mark Murcko was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Director Lonnel Coats was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Chief Financial Officer Thomas Catinazzo sold 17,717 shares of Relay Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 1,490 shares to cover tax obligations related to RSU vesting.

Relay Therapeutics CFO Thomas Catinazzo reported transactions involving the sale of common stock and the acquisition of stock options, executed under a pre-arranged Rule 10b5-1 trading plan.

Relay Therapeutics' President of R&D, Donald A. Bergstrom, sold shares to cover tax obligations related to routine restricted stock unit vesting.

Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, reported routine stock acquisitions via ESPP and sales to cover tax obligations from RSU vesting.

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, sold shares of common stock on January 27 and 28, 2026, to cover income tax withholding obligations related to RSU vesting.

Relay Therapeutics, Inc. granted 575,000 stock options to Donald A. Bergstrom, President of R&D, with an exercise price of $7.94.

Relay Therapeutics, Inc. granted 475,000 stock options to Chief Corporate Development Officer Peter Rahmer with an exercise price of $7.94, vesting quarterly after January 13, 2026.